Speaker illustration

Professor Emanuela Teresa Locati

IRCCS San Donato Polyclinic, Milan (Italy)

Member of:

European Society of Cardiology
European Heart Rythm Association

Main field of activity the study of pathogenetic mechanisms, diagnosis and therapy of arrhythmogenic disorders. Initially active as Coordinator for the International Prospective Registry of the Long QT syndrome (LQTS), established jointly in Milan, Italy and Rochester, NY, involved in pioneering studies on the epidemiologic, electrocardiographic and genetic aspect of the congenital LQTS. Later dedicated to the development of new devices for the noninvasive diagnosis of rare cardiac arrhythmic diseases. Currently involved in telemedicine and remote monitoring of cardiac implantable electric devices (cardiac implantable defibrillator and implantable cardiac monitors) and in cardiogenetics of channelopathies (mainly Brugada Syndrome and LQTS) and cardiomyopathies (mainly hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy). Fluent in Italian, English, and French. Scopus Metric Overview: 105 Documents, 9539 Citations by 5237 documents, 41 h-index.

ECG and holter variables – Practical utilities

Event: ESC Congress 2022

Topic: Diagnostic Methods

Session type: Moderated ePosters

Thumbnail

Wearables and m-Health in atrial fibrillation and heart failure

Event: ESC Congress 2022

Topic: Wearables and m-Health

Session type: Moderated ePosters

Thumbnail

Diagnosis, prediction, and mechanism of atrial fibrillation

Event: ESC Congress 2022

Topic: Diagnostic Methods

Session type: Moderated ePosters

Thumbnail

Risk stratification for sudden death in ischaemic and non-ischaemic cardiomyopathy

Event: ESC Congress 2017

Topic: Ventricular arrhythmias

Session type: Advances in Science

Thumbnail

New technologies for prolonged ECG monitoring: how, when and for whom?

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: ECG (Cardiac arrhythmias, non invasive)

Session type: Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb